Business Wire

TECNOTREE

7.8.2024 11:59:35 CEST | Business Wire | Press release

Share
Tecnotree Recognized in 3 Different 2024 Gartner® Hype Cycle™ Reports, for Partner Ecosystem Management Platforms for CSPs, CSP Digital Marketplaces, and AI for CSP Customer Interactions Categories

Tecnotree, a global leader in digital platforms and services for AI, 5G, and cloud-native technologies, has been mentioned in three different 2024 Gartner Hype Cycle reports, recently published. Tecnotree has been cited under the categories of Hype Cycle for Enterprise Communication Services, Private Mobile Network Services, and Operations and Automation in Communications Industry, 2024. We believe that these recognitions highlight Tecnotree’s excellence in Partner Ecosystem Management Platforms for CSPs and CSP Digital Marketplaces for Tecnotree Moments Partner Ecosystem Platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807343127/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Tecnotree Recognized in 3 Different 2024 Gartner® Hype Cycle™ Reports, for Partner Ecosystem Management Platforms for CSPs, CSP Digital Marketplaces, and AI for CSP Customer Interactions Categories (Graphic: Business Wire)

As per Gartner, “Gartner Hype Cycles provide a graphic representation of the maturity and adoption of technologies and applications, and how they are potentially relevant to solving real business problems and exploiting new opportunities. Gartner Hype Cycle methodology gives you a view of how a technology or application will evolve over time, providing a sound source of insight to manage its deployment within the context of your specific business goals.” Digital marketplaces are an increasingly important part of the CSPs’ go-to-market strategy for digital services and small-and-midsize-business (SMB) and consumer segments. CSPs can enrich their offerings with partner solutions, drive data insights on buyer behavior, and implement automation for faster cycles and improved digital engagement. CSPs can use marketplaces to differentiate from competitors through expanding portfolio with partner offerings, ease-of-use, automation, composable bundles, verticalization and locally tailored offerings.

Tecnotree Moments powered by TM Forum certified Open APIs and Open Digital Architecture (ODA) compliant, provides superior digital experience management operations with advertising and partner led campaign management solutions for aim driven product recommendations, customer journey orchestration, partner management, content and channel personalisation, and dynamic loyalty programs. The Tecnotree Moments multi experience platform using Azure and AWS cloud infrastructure with multitenancy capabilities. The low/no code platform provides intelligence enabled customer experience, based on AI & ML and automation utilizing cloud technologies.

Tecnotree Moments, marketplace accelerates time to market, extends outreach to target segments, expands partner ecosystems, and speeds up the sales cycle. For CSPs, marketplaces target increased self-service and digital engagement, revenue growth, tailored solutions that can be composed based on the needs of each buyer, and actionable data insights on purchase behavior that can inform product developers and enrich the support of ecosystem partners.

Padma Ravichander, CEO, Tecnotree Corporation said, “We are thrilled to be acknowledged in three of the Gartner Hype Cycles. We believe that this recognition underscores our forward-looking vision unwavering commitment to delivering unparalleled value by redefining digital experiences and enhancing revenue monetization capabilities for our customers. Leveraging AI, 5G, and cloud-native technologies, we drive innovation that empowers CSPs with personalized, highly secure solutions. Our inclusion in these reports validates our dedication to pushing the boundaries and continuously expanding our use of AI applications to improve productivity, efficiency, and customer experience.”

Gartner, Hype Cycle for Customer Experience and Monetization in the Communications Industry, 2024, By Susan Welsh de Grimaldo, Pulkit Pandey, 25 July 2024.

Gartner, Hype Cycle for Enterprise Communication Services, 2024, By Khurram Shahzad, 16 July 2024.

Gartner, Hype Cycle for Operations and Automation in the Communications Industry, 2024, By Mounish Rai, Amresh Nandan, 23 July 2024.

Gartner Research Methodologies, Gartner Hype Cycle, August 5, 2024, https://www.gartner.com/en/research/methodologies/gartner-hype-cycle

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Tecnotree

Tecnotree is a 5G-ready digital Business Support System (BSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree leads the way on the TM Forum Open API Conformance with 59 certified Open APIs including 9 real-world open APIs, a testament to the company's commitment to excellence, and continuously striving to deliver differentiated experiences and services to both CSPs and DSPs. Our agile and open-source digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on the Helsinki Nasdaq (TEM1V).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240807343127/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye